about
Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosisEffect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failurePrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesHepatic stellate cells: protean, multifunctional, and enigmatic cells of the liverMechanisms of hepatic fibrogenesisEndothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.Nitric oxide synthase and heme oxygenase expressions in human liver cirrhosisTumor necrosis factor α stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway.Integrin-linked kinase regulates endothelial cell nitric oxide synthase expression in hepatic sinusoidal endothelial cells.Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.Management of cardiopulmonary complications of cirrhosis.Sensitivity to endothelin-1 is decreased in isolated livers of endothelial constitutive nitric oxide synthase knockout mice.Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.Role of endothelin in systemic and portal resistance in cirrhosis.Transcriptional regulation of stellate cell activation.Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.Current and future anti-fibrotic therapies for chronic liver disease.Pros and cons of L-arginine supplementation in disease.Advances in antifibrotic therapy.Portal hypertensive response to kinin.Non-invasive assessment of liver fibrosis: it is time for laboratory medicine.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapiesProtective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.Angiogenesis in liver regeneration and fibrosis: "a double-edged sword".The stellate cell system (vitamin A-storing cell system).K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.Postreperfusion microcirculatory derangements after liver transplantation: Relationship to hemodynamics, serum mediators, and outcome.Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers.The endothelin-1 receptor-mediated pathway is not involved in the endothelin-1-induced defenestration of liver sinusoidal endothelial cells.Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C.The Molecular Basis of Portal Hypertension.Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.Fibronectin stimulates endothelin-1 synthesis in rat hepatic myofibroblasts via a Src/ERK-regulated signaling pathway.Focal adhesion disassembly is an essential early event in hepatic stellate cell chemotaxis.Fate of bradykinin on the rat liver when administered by the venous or arterial route.Protective effects of simultaneous splenectomy on small-for-size liver graft injury in rat liver transplantation.Effects of sildenafil citrate on hepatic function and regeneration in normal and alcohol-fed rats.[Ca2+]i-independent contractile force generation by rat hepatic stellate cells in response to endothelin-1.Roles of anandamide in the hepatic microcirculation in cirrhotic rats.Dual cytoprotective effects of splenectomy for small-for-size liver transplantation in rats.
P2860
Q24293659-190B9787-592F-4D2C-9468-57F60177ADFDQ27499349-0D4E5729-2F3D-40C5-AC5E-4783332E9BAEQ28272678-FA243958-D9A6-49C5-9F1D-CF753018DCF7Q29616840-6DF3E45A-8D00-4912-9E1B-1B9E6F14745AQ29619336-92DBB86D-2E8F-4B7D-9AAF-A7E86A75735BQ30488861-9C5EB6C6-9FE2-4441-8D31-0D18BB8CF9D7Q33788328-958536FC-2139-45A7-8494-99279C80ACDBQ34093107-1D0DF43C-5E68-4916-B002-C1EB81D13A24Q34644767-488BF42E-277F-49DF-87E6-FE4D17A815A0Q35136411-06970DE5-8D1B-4D60-8FF1-AF4EDF4AE9D4Q35207515-04818DC2-5322-4409-A75D-36DCA8DBAF8AQ35220034-F359033A-BF80-4D25-982E-43D2732C9356Q36304061-1057F274-97B8-4609-96E5-3AE979F5D698Q36564609-8ECFC50C-AC34-48D4-A245-434D6B65D840Q36588242-42899C09-B063-4819-874B-7F6B72D613BCQ36759223-F87438DD-0805-418B-84D3-DCB7DCBA897BQ37317654-BA38AD52-DC19-43C1-8870-AB9E5D0907D9Q37350078-02CC76E0-4A64-449B-9261-291599791FB8Q37353099-2D07586E-DF41-408D-B243-7B546A4C29ECQ37590180-EC902F68-0140-4CBA-A3E6-CB359EA94CEBQ37801658-AB2A7238-D311-43D3-8522-18B15BED5301Q38073028-A2165DDC-73C6-4E9D-A290-96F54152C2CFQ38326327-E408D948-5926-4C50-8DA1-2673C702930AQ38552296-16EBD8D9-158A-4E87-8A4F-7ACE495EB789Q38744473-307399F0-AB35-4B54-B895-658F49018353Q38957437-7F44813E-2DF5-4C5D-98E2-DE59044C337DQ39028867-17873C15-A6D9-47DE-8D53-0C42B7A9BA6AQ39408396-47FC2F09-32B8-4255-BF30-524A9D16421CQ39774817-C0FB96DE-AE4C-4C81-AEB3-6E882FAE7218Q40211269-4549BD5C-1C8F-4CB8-BD7A-11ECE9284B4AQ41112424-59CC9686-97B5-4531-8B29-B9DD164D308FQ41416491-69996FF4-AE30-4E1F-A404-DE98D6A0C071Q42455012-CBD29086-45D8-4ACF-A7EA-400FFC14C6CDQ45228299-76707197-A1DA-4EBA-99F6-1BA477544C94Q45289772-C322452D-5679-46CE-BF26-190D4FC762E6Q45789352-CFF2BAFF-7918-49E7-87A8-B45608D07D23Q46584657-9C758E69-64D7-44BE-9841-E58D40BD3A7CQ46669933-56556963-0B1F-4027-A233-C21467302373Q46890652-F6F88EF4-CF4D-496C-AD2C-290B4FF1D511Q47294409-769583EE-2FB4-4CA8-B158-C0A19BBF2B60
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vascular mediators in the injured liver.
@ast
Vascular mediators in the injured liver.
@en
type
label
Vascular mediators in the injured liver.
@ast
Vascular mediators in the injured liver.
@en
prefLabel
Vascular mediators in the injured liver.
@ast
Vascular mediators in the injured liver.
@en
P356
P1433
P1476
Vascular mediators in the injured liver.
@en
P2093
Don C Rockey
P356
10.1053/JHEP.2003.50044
P407
P577
2003-01-01T00:00:00Z